Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Ileus 1

Interventions

Gemcitabine 157Cisplatin 116pembrolizumab 80Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Cystectomy 40Docetaxel 38atezolizumab 33Magnetic Resonance Spectroscopy 31durvalumab 30Radiotherapy 29BCG Vaccine 26avelumab 24Specimen Handling 24Doxorubicin 23enfortumab vedotin 22Fluorouracil 20Cystoscopy 20Methotrexate 17Vinblastine 16Standard of Care 15Filgrastim 14Transurethral Resection of Bladder 13Sunitinib 13Ipilimumab 13vinflunine 125-aminolevulinic acid hexyl ester 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Urinary Bladder Neoplasms × Urinary Diversion × Clear all
NCT05241340 2025-10-24

RAD-VACCINE

The Methodist Hospital Research Institute

Phase 2 Active not recruiting
33 enrolled
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT06928220 2025-04-15

CIMMIS

Fundacio Puigvert

Phase NA Completed
120 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ileus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡